Showing results (21-30 of 287) with videos related to
Sort By:
Pageof 29
Expert Opinion on Pharmacotherapy|June 9, 2020
Management of cardiovascular disease in patients with systemic lupus erythematosusParamarjan Piranavan, Andras PerlAutoimmunity Reviews|August 30, 2008
Metabolic control of T cell activation and death in SLEDavid Fernandez, Andras PerlCurrent Opinion in Rheumatology|January 3, 2020
Metabolic pathways mediate pathogenesis and offer targets for treatment in rheumatic diseasesBrandon Wyman, Andras PerlAutoimmunity|October 17, 2013
Metabolic control of the epigenome in systemic Lupus erythematosusZachary Oaks, Andras PerlCurrent Opinion in Rheumatology|April 4, 2026
Pathogenesis-directed lupus therapeuticsBhavya Poudyal, Andras PerlFrontiers in Immunology|March 25, 2021
Double-Edged Sword: Interleukin-2 Promotes T Regulatory Cell Differentiation but Also Expands Interleukin-13- and Interferon-γ-Producing CD8<sup>+</sup> T Cells <i>via</i> STAT6-GATA-3 Axis in Systemic Lupus ErythematosusHiroshi Kato, Andras PerlClinical Immunology (Orlando, Fla.)|June 18, 2021
Improvement of renal and non-renal SLE outcome measures on sirolimus therapy - A 21-year follow-up study of 73 patientsParamarajan Piranavan, Andras PerlClinical Immunology (Orlando, Fla.)|January 13, 2006
The role of nitric oxide in abnormal T cell signal transduction in systemic lupus erythematosusGyorgy Nagy, Andras PerlExpert Opinion on Pharmacotherapy|June 10, 2009
Pharmacotherapy of systemic lupus erythematosusLisa Francis, Andras PerlJournal of Immunology (Baltimore, Md. : 1950)|April 1, 2014
Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosusHiroshi Kato, Andras PerlPageof 29